Raj Mehta

Dr. Mehta has over 15 years’ experience in identifying, nurturing and partnering early stage technologies in Biotech and Pharma Industry. At Cancer Research Technology (CRT), Raj has led portfolio management and commercialization of a broad range of oncology focused therapeutic and diagnostic assets. He led formation of and undertaken executive and non-executive roles in BliNK Therapeutics and Revitope. Prior to joining CRT, he was Group Leader in the E. Merck Laboratory at MRC Collaborative Centre (London) leading groups supporting anti-angiogenesis and cardiovascular drug discovery projects for Merck KGaA (Darmstadt).